Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Menopause

• Publication date

  2003-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.GME.0000063566.84134.98PMID 14501606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of Fibrinogen on Cardiovascular Disease

  2012cited by this paper
• How Many Women Have Osteoporosis?

  2005cited by this paper
• Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial

  2003influential reference
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events*

  2002cited by this paper
• The protective effects of estrogen on the cardiovascular system.

  2002influential reference
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.

  2001cited by this paper
• Homocysteine and atherothrombosis

  2001cited by this paper
• Postmenopausal hormone therapy for prevention of fractures: how good is the evidence?

  2001cited by this paper
• Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

  2001cited by this paper
• Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women.

  2001cited by this paper
• Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.

  2001cited by this paper
• Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels.

  2000cited by this paper
• Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats1.

  2000cited by this paper
• Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial

  2000cited by this paper
• Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator

  2000cited by this paper
• Lipoproteins in health and disease

  2000influential reference
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Baseline diene conjugation in LDL lipids: an indicator of circulating oxidized LDL.

  1999cited by this paper
• Adverse events reported by postmenopausal women in controlled trials with raloxifene.

  1999cited by this paper
• Stable over-expression of estrogen receptor-α in ECV304 cells inhibits proliferation and levels of secreted endothelin-1 and vascular endothelial growth factor

  1999cited by this paper
• Protective effects of estrogen on the cardiovascular system.

  1999cited by this paper
• Stable over-expression of estrogen receptor-alpha in ECV304 cells inhibits proliferation and levels of secreted endothelin-1 and vascular endothelial growth factor.

  1999cited by this paper
• Randomized Comparison of Oral and Transdermal Hormone Replacement on Carotid and Uterine Artery Resistance to Blood Flow

  1998cited by this paper
• Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

  1998cited by this paper
• The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane.

  1998cited by this paper
• The Effect of Estrogen Replacement Therapy on Plasma Nitric Oxide and Endothelin-1 Levels in Postmenopausal Women

  1998cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Homocysteine and atherothrombosis.

  1998cited by this paper
• Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.

  1997cited by this paper
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

  1997cited by this paper
• Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors.

  1997cited by this paper
• The calcium-dependent nitric oxide production of human vascular endothelial cells in preeclampsia.

  1996cited by this paper
• Hyperinsulinemia 17 years after preeclamptic first pregnancy.

  1996cited by this paper
• Hormone replacement therapy modifies the capacity of plasma and serum to regulate prostacyclin and endothelin-1 production in human vascular endothelial cells.

  1996cited by this paper
• Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects.

  1995cited by this paper
• 17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells.

  1995cited by this paper
• Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study.

  1995cited by this paper
• Blood Coagulation and Fibrinolysis Activation during Sudden Arterial Occlusion of Lower Extremities – an Association with Ischemia and Patient Outcome

  1995cited by this paper
• Postmenopausal hormonal replacement decreases plasma levels of endothelin-1.

  1995cited by this paper
• Up‐regulation of nitric oxide synthase by estradiol in human aorticendothelial cells

  1995cited by this paper
• Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction.

  1994cited by this paper
• Induction of calcium-dependent nitric oxide synthases by sex hormones.

  1994cited by this paper
• Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group.

  1993cited by this paper
• Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.

  1993cited by this paper
• Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women

  1992cited by this paper
• Perspective how many women have osteoporosis?

  1992cited by this paper
• Thromboxane dominance and prostacyclin deficiency in habitual abortion

  1991cited by this paper
• Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.

  1989cited by this paper
• Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.

  1983cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact

  year unknowncited by this paper

• Pharmacotherapeutic options for the treatment of menopausal symptoms

  2021cites this paper
• Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy

  2017cites this paper
• Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data

  2017influential citation
• Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials

  2017cites this paper
• Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER.

  2016cites this paper
• Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause

  2016cites this paper
• Selektive Östrogenrezeptormodulatoren (SERM)

  2015cites this paper
• Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.

  2014influential citation
• Use of SERMs for treatment in postmenopausal women.

  2014cites this paper
• Ospemifene in the Treatment of Vulvovaginal Atrophy

  2014cites this paper
• The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.

  2014cites this paper
• Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause

  2014cites this paper
• Ospemifene: First Global Approval

  2013influential citation
• Ospemifene, vulvovaginal atrophy, and breast cancer.

  2013cites this paper
• Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis

  2013cites this paper
• The Effects of Estradiol, Androgens and the Selective Estrogen Modulators: Ospemifene, Raloxifene and Tamoxifen on Explant Cultures of Human Breast Tissue

  2013cites this paper
• Emerging Selective Estrogen Receptor Modulators

  2012cites this paper
• Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model

  2012cites this paper
• One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus

  2012cites this paper
• Tamoxifen and its new derivatives in cancer research.

  2011cites this paper
• SERMs: progress and future perspectives.

  2010cites this paper
• Postmenopausal hot flushes, vascular health and hormone therapy

  2010cites this paper
• What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

  2010cites this paper
• Pharmacologic evaluation of ospemifene

  2010influential citation
• Effect of hormone replacement therapy on inflammatory biomarkers.

  2009cites this paper
• Ospemifene use in postmenopausal women

  2009cites this paper
• Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study

  2009cites this paper
• Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

  2009cites this paper
• Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings

  2008cites this paper
• Pharmacologic effects of ospemifene in rhesus macaques: a pilot study.

  2008cites this paper
• The effects of selective estrogen receptor modulators on the death of breast cancer cells and osteoblastic cells

  2008cites this paper
• Selective estrogen receptor modulators and risk for coronary heart disease

  2007cites this paper
• The risk for cardiovascular disease in women: from estrogens to selective estrogen receptor modulators.

  2007cites this paper
• Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis

  2007cites this paper
• Cardiovascular Disease and SERMs

  2006cites this paper
• Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women

  2006cites this paper
• Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

  2006cites this paper
• The Cardiovascular Effects of Selective Estrogen Receptor Modulators

  2006cites this paper
• Clinical Pharmacology of Selective Estrogen Receptor Modulators (SERMs)

  2006cites this paper
• Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.

  2005cites this paper
• Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women

  2005cites this paper
• The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.

  2005cites this paper
• Phytoestrogens in Postmenopausal Women : Effects on Climacteric Symptoms, Reproductive Organs, and Markers of Bone and Vascular Health

  2004cites this paper
• Gateways to clinical trials.

  2004cites this paper
• Vascular biology of estrogen receptors alpha and beta : -An experimental approach to restenosis and transplant arteriosclerosis

  2004cites this paper
• Selective estrogen receptor modulators prevent neointima formation after vascular injury.

  2004cites this paper
• Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women

  2004cites this paper
• Gateways to clinical trials.

  2003cites this paper
• Send Orders of Reprints at Reprints@benthamscience.net the Discovery and Development of Selective Estrogen Receptor Modulators (serms) for Clinical Practice the Biological Basis of Serm Action: Target Tissue Specific Actions

  year unknowncites this paper
• International Journal of Women's Health Dovepress Video Abstract Ospemifene for the Treatment of Dyspareunia Associated with Vulvar and Vaginal Atrophy: Potential Benefits in Bone and Breast

  year unknowncites this paper